Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €30.85 EUR
Change Today +0.52 / 1.70%
Volume 410.4K
As of 4:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (SAZ) Snapshot

Open
€30.23
Previous Close
€30.33
Day High
€31.18
Day Low
€30.08
52 Week High
07/3/14 - €36.24
52 Week Low
12/17/14 - €24.10
Market Cap
1.9B
Average Volume 10 Days
468.3K
EPS TTM
€1.08
Shares Outstanding
60.7M
EX-Date
06/4/15
P/E TM
28.6x
Dividend
€0.66
Dividend Yield
2.14%
Current Stock Chart for STADA ARZNEIMITTEL AG (SAZ)

Related News

No related news articles were found.

stada arzneimittel ag (SAZ) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (SAZ) Details

STADA Arzneimittel AG engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s principal products include Omeprazole, a stomach medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Atorvastatin, an antilipemic; and Phospholipide, a liver medicine. The Branded Products segment offers non-prescription products. This segment primarily provides APO-go, a Parkinson medicine; Aqualor, a cold medicine based on seawater; Grippostad, a cold medicine; Snup, a nasal preparation; and Ladival, a sunscreen product. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.

9,825 Employees
Last Reported Date: 03/26/14
Founded in 1895

stada arzneimittel ag (SAZ) Top Compensated Officers

Chairman of The Executive Board
Total Annual Compensation: €2.8M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.1M
Chief Business Development & Central Services...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2014.

stada arzneimittel ag (SAZ) Key Developments

Stada-Arzneimittel Ag Reports Preliminary Group Earnings Results for the Year 2014; Provides Earnings guidance for 2015

Stada-Arzneimittel AG reported preliminary group earnings results for the year 2014. Group sales were €2,062.2 million against €2,003.9 million a year ago. Operating profit was €251.5 million against €202.1 million a year ago. Operating profit, adjusted was €306.3 million against €266.2 million a year ago. In 2014, reported operating profit decreased significantly by 24% to €188.5 million against €248.3 million a year ago, mainly due to impairments of goodwill in the market regions CIS/Eastern Europe as well as Asia/Pacific & MENA. EBITDA was €418.8 million against €382.6 million a year ago. EBITDA, adjusted was €431.9 million against €414.3 million a year ago. Net income was €64.6 million against €121.4 million a year ago. Net income, adjusted was €186.2 million against €160.6 million a year ago. Earnings per share were €1.07 against €2.04 a year ago. Earnings per share, adjusted were €3.08 against €2.70 a year ago. Cash flow from operating activities amounted to €223.8 million in the reporting year against €203.7 million a year ago. For the outlook for 2015, the Executive Board anticipates slight growth in Group sales adjusted for currency and portfolio effects. The Executive Board however expects a decreased earnings contribution from Russia due to the recent developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation. Taking these developments into account and based on current currency relations, the Executive Board expects a substantial decrease in adjusted EBITDA and adjusted net income. The Executive Board expects the ratio of net debt excluding further acquisitions to adjusted EBITDA to be at a level of nearly 3 in 2015.

Stada-Arzneimittel Ag Provides Unaudited Preliminary Earnings Guidance for the Year 2014 and 2015; Provides Dividend Guidance for Fiscal 2014

Stada-Arzneimittel AG provided unaudited preliminary earnings guidance for the year 2014. Group sales is expected to have risen by 3% to €2,062.2 million; Reported EBITDA is expected to have increased by 9% to €418.8 million; adjusted EBITDA is anticipated to have increased by 4% to €431.9 million. Overall, there were one-time special effects in the expected amount of €128.6 million before or €121.6 million after taxes. They include impairments on goodwill in the expected amount of €54.0 million before and after taxes as well as on further intangible assets in the expected amount of €22.0 million before and €21.7 million after taxes as a result of the significantly changed interest rate and currency environment as well as ongoing higher risks in the market region CIS/Eastern Europe. In light of this, reported net income is expected to have decreased by 47% to €64.6 million; Adjusted net income is anticipated to have increased by 16% to €186.2 million. Reported earnings per share are anticipated to have decreased to €1.07; and Adjusted earnings per share are expected to have increased to €3.08. As of the balance sheet date, net debt is expected to amount to €1,327.5 million; Cash flow from operating activities is expected to have amounted to €223.8 million in financial year 2014; Free cash out flow is anticipated to have amounted to €38.2 million; Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals is expected to have amounted to €157.4 million. For the preliminary outlook for 2015, the Executive Board currently anticipates growth in Group sales adjusted for currency and portfolio effects. From today's perspective, the Executive Board however expects a decreased earnings contribution from Russia due to the recent developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation. Taking these developments into account and based on current currency relations, the Executive Board expects from the current perspective a substantial decrease in adjusted EBITDA and adjusted net income. Due to the decreased net income reported, the STADA Executive Board recommends that the Supervisory Board propose to the next Annual General Meeting on June 3, 2015 an unchanged dividend of €0.66 per common share for financial year 2014 against €0.66 for the last year. The resulting total dividend payment of €40.0 million reflects a significantly higher distribution ratio than the previous year at approximately 62% of net income reported.

Stada-Arzneimittel AG to Report Fiscal Year 2014 Results on Mar 26, 2015

Stada-Arzneimittel AG announced that they will report fiscal year 2014 results on Mar 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZ:GR €30.85 EUR +0.52

SAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 719.00 GBp -3.50
Richter Gedeon Nyrt 3,952 -68.00
Oxford Biomedica PLC 11.00 GBp -1.37
Skyepharma PLC 310.75 GBp -4.50
Vernalis PLC 46.50 GBp +1.00
View Industry Companies
 

Industry Analysis

SAZ

Industry Average

Valuation SAZ Industry Range
Price/Earnings 12.5x
Price/Sales 0.8x
Price/Book 1.6x
Price/Cash Flow 12.4x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit www.stada.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.